Hurthle Cell Carcinoma Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Hurthle Cell Carcinoma Treatment Market is segmented By Stage (Stage I, Stage II, Stage III, Stage IV) By Treatment (Surgery, Radioactive Iodine Therapy, Hormone Therapy, Targeted Therapy, Immunotherapy, Others) By End Users (Hospitals, Ambulatory Surgical Centers, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

Global Hurthle Cell Carcinoma Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2031 growing with a CAGR of YY% during the forecast period 2024-2031.

Hurthle cell carcinoma represents about 5% of all differentiated thyroid carcinomas and is seen more frequently in females than in men. The global hurthle cell carcinoma treatment market has witnessed significant growth in recent years due to the adoption of targeted therapy. For instance, iodine-131 is used in the radioactive iodine treatment for hurthle cell carcinoma.

Furthermore, significant growth drivers such as increasing drug approvals, and rising research and developments give rise to future market growth. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experiencing a rise in demand from North American regions. Significant key players like Pfizer Inc., Sanofi S.A., AstraZeneca, and others are actively operating in the market.

Market Scope

For more details on this report - Request for Sample

Market Dynamics

Increasing Research and Developments  for Hurthle Cell Carcinoma Treatment 

The global hurthle cell carcinoma treatment market has witnessed significant growth due to various recent research and developments. Hurthle cell carcinoma is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating hurthle cell carcinoma help to accelerate market growth.

For instance, according to the Springer Journal, an article entitled Lenvatinib as a Promising Treatment Option for Unresectable Hürthle Cell Carcinoma published in April 2023 states that tyrosine kinase inhibitor called Lenvatinib is effective in treating unresectable hurthle cell carcinoma and can significantly increase progression-free survival. In a recent study, the patient showed positive results with lenvatinib therapy with a progression-free duration of 30 months which shows a significant reduction in the size of the cancer. 

Rising Approvals of Drugs for Hurthle Cell Carcinoma Treatment is Expected to Boost the Market Growth 

The increase in drug approvals by regulatory bodies helps to drive market growth. Hurthle cell carcinomas are characterized by capsular invasion, vascular invasion, infiltration of the thyroid gland or distant lymph nodes, and metastatic spread. About 33% of hurthle cell tumors demonstrate signs of invasive growth that indicate malignancy and the possibility of metastasis.

For instance, in October 2022, Innovent Biologics, Inc announced that the National Medical Products Administration (NMPA) of China approved the New Drug Application (NDA) for selpercatinib for the treatment of adult patients with advanced or metastatic thyroid cancer with a RET gene fusion which requires systemic therapy. Thus, owing to the above factors the market is expected to boost over the forecast period.

Complications Associated with Hurthle Cell Carcinoma are Expected to Hamper Global Market Growth 

Hurthle cell carcinomas can cause complications in the neck by local invasion into the larynx, vocal cords, esophagus, trachea, or mediastinum and by compression of major nerves and vessels in the neck from bulky adenopathy. Metastasis of this tumor tends to occur in lymph nodes, lungs, bone, and the brain. Thus, owing to the above factors the market is expected to hamper over the forecast period.

Segment Analysis

The global hurthle cell carcinoma treatment market is segmented based on stage, treatment, end users and region.

Radioactive Iodine Therapy from the Treatment Segment Accounted for Approximately 38.5% of the Global Hurthle Cell Carcinoma Treatment Market Share 

The rising clinical trials of radioactive iodine therapy globally have contributed to the growing demand for hurthle cell carcinoma treatment. Radioactive iodine therapy is a reliable treatment that targets thyroid cells by giving less exposure to other body cells. This therapy works by using radioactive iodine that kills any remaining thyroid cancer cells that might remain after surgery. 

For instance, according to clinicalTrials.gov, on July 11, 2023, the Hospital of Xiamen University conducted a clinical trial on the Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer. This study was designed to evaluate the safety, tolerability, and maximum tolerated dose of a long-lasting radiolabeled fibroblast activation protein inhibitor 177Lu-DOTA-EB-FAPI in mRAIR-TC patients with PD after TKIs treatment.

Geographical Penetration

North America Accounted for Approximately 40.4% of the Market Share in 2022

North America has maintained a significant proportion of the hurthle cell carcinoma treatment market in recent years, and this trend is anticipated to continue throughout the forecast period due to the factors such as a high prevalence of thyroid cancers, increasing research and developments, and technological advancements in hurthle cell carcinoma treatment.

For instance, according to the American Cancer Society, the estimation for thyroid cancer in the United States for 2023 is about 43,670 new cases of thyroid cancer (12,440 in men and 31,170 in women) and around 2,120 deaths from thyroid cancer (980 in men and 1,260 in women). Thus, the above factors help to boost the region's growth.

Competitive Landscape

The major global players in the market include Bayer Healthcare Pharmaceuticals, Amgen Inc., Sanofi S.A, AstraZeneca, Novartis AG, Eli Lily and Company, Hikma Pharmaceuticals, Pfizer Inc., Genentech Inc., Blueprint Medicines among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the hurthle cell carcinoma treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in hurthle cell carcinoma treatment research. Clinical trials are vital for developing new treatments and improving outcomes in the hurthle cell carcinoma treatment market. 

However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the hurthle cell carcinoma treatment market is expected to be moderately affected over the forecast period.

Key Developments

• In June 2023, SCOR announced the launch of the Vitae Thyroid Cancer Risk Calculator, a new addition to SCOR’s biometric risk calculators. Vitae Thyroid Cancer Risk Calculator was developed as an API that can be easily implemented with digital underwriting solutions from our insurance partners around the world.
• In April 2023, Apollo Cancer Centre launched the advanced radionuclide therapy for the treatment of thyroid cancer at a symposium. Radionuclide Therapy (RNT) is a new treatment option in the multidisciplinary management of cancer that involves using radiation to target and destroy cancer cells.
• In September 2022, The U.S. Food and Drug Administration (FDA) granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in the selection of patients with RET-fusion positive advanced or metastatic medullary thyroid cancer (MTC).

Why Purchase the Report?

• To visualize the global hurthle cell carcinoma treatment market segmentation based on the stage, treatment, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of global hurthle cell carcinoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hurthle cell carcinoma market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies